CD274 and neoplasm: More, a longer PFS (2.1 months) in the T790M-negative patients than the T790M-positive patients (1.3 months) was seen, and the former also had a higher proportion of tumors with a PD-L1 expression along with higher CD8+ tumor infiltration and TMB (95).